

Dose-ranging study of SCH34117 in the treatment of patients with seasonal allergic rhinitis

Submission date 02/08/2002	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 02/08/2002	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 06/09/2007	Condition category Respiratory	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Heribert Staudinger

Contact details
Medical officer
Schering-Plough Research Institute (SPRI)
2015 Galloping Hill Road, K-15-4
Kenilworth
United States of America
NJ 07033-0530

Additional identifiers

Protocol serial number
C98-001

Study information

Scientific Title

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Seasonal allergic rhinitis

Interventions

Patients randomly assigned once-daily (QD) SCH34117 at doses of 2.5, 5, 7.5, 10, or 20 mg versus placebo for two weeks.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

SCH34117

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/06/1998

Eligibility**Key inclusion criteria**

Subjects 12 years or older with a two-year documented history of seasonal allergic rhinitis and otherwise in good health

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/04/1998

Date of final enrolment

01/06/1998

Locations

Countries of recruitment

United States of America

Study participating centre

Medical officer

Kenilworth

United States of America

NJ 07033-0530

Sponsor information

Organisation

Schering-Plough Research Institute (SPRI) (USA)

ROR

<https://ror.org/02891sr49>

Funder(s)

Funder type

Industry

Funder Name

Schering-Plough Research Institute (SPRI) (USA)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	05/08/2002		Yes	No